Gujarat Inject Kerala Reports Q2 Profit of Rs 0.73 Crore

Revenue: Rs 5.82 crore (Q2 FY27) | Net Profit: Rs 0.73 crore (Q2 FY27)

Reader Takeaway: Expansion plans via warrants are countered by auditor warnings regarding significant, long-overdue trade receivables requiring potential write-offs.

What just happened

Gujarat Inject Kerala Ltd announced its financial results for the quarter and half-year ending September 30, 2026. Simultaneously, the board approved an increase in authorized share capital from Rs 15 crore to Rs 17.63 crore and authorized a preferential issue of equity warrants worth up to Rs 3 crore to non-promoter investors.

Why this matters

The company is looking to strengthen its balance sheet through fresh capital infusion. However, this is overshadowed by a qualified opinion from statutory auditors, M/s. S. Mandawat & Co., concerning Rs 5.74 crore in trade receivables that have been outstanding for over a year. The company has not made any provision for expected credit losses on these amounts, despite the auditor's insistence.

Risks to watch

Investors should be cautious of the auditor-flagged trade receivables. If these dues prove irrecoverable, the company may be forced to make significant provisions, which would directly impact future earnings. Furthermore, the upcoming preferential issue of warrants will lead to equity dilution for existing shareholders once the conversion occurs.

Context metrics

For the half-year ending September 30, 2026, the company generated Rs 18.27 crore in revenue and Rs 1.98 crore in net profit. The company recently completed a share split, moving from a face value of Rs 10 to Rs 1, which is now reflected in all EPS and share data.

What to track next

Shareholders should look for official announcements regarding the pricing of the preferential warrants and monitor subsequent quarterly updates for any progress in the collection of the Rs 5.74 crore in long-standing trade receivables.